HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Etodolac

HCID 3308
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
41340-25-4
Standard SMILES
CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
InChIKey
NNYBQONXHNTVIJ-UHFFFAOYSA-N
Molecular formula
C17H21NO3
Average molar mass
287.35 g/mol
Monoisotopic mass
287.15214353

Overview

Etodolac can cause developmental toxicity and female reproductive toxicity according to state or federal government labeling requirements.

Names & identifiers

Preferred name
Etodolac
IUPAC
2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
English name
Etodolac
Molecular formula
C17H21NO3
Molecular weight
287.35

Names & synonyms

etodolac41340-25-4Etodolic acidLodineUltradolLodine XLEdolanRamodarEtodolacoZedolacAY-24236Etodolacum
Show more names
HypenEtopenRAK-591OstelucEtodineay24236
FlancoxTedolanAY 24236AY-24,236EccoxolacNapilacLodin xl1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid

Database identifiers

CAS
41340-25-4
PubChem CID
3308
DTXSID
DTXSID9020615
ChEMBL
CHEMBL622
ChEBI
CHEBI:4909
UNII
2M36281008
EC Number
629-689-1
Nikkaji
J16.541G

Properties

Computed structural properties

XLogP
2.8
Topological polar surface area
62.3 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
3
Rotatable bonds
4
Heavy atoms
21
Formal charge
0
Complexity
399

Experimental & physicochemical properties

Drugs · 3 items

DEA NFLIS-Drug Category -> Analgesics

Pharmaceuticals

Pharmaceuticals -> Used in Switzerland

LogP · 2 items

2.5

2.75

Solubility3.92e-02 g/L
Human Drugs · 4 items

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Animal DrugsActive Ingredients (Etodolac) -> FDA Greenbook
Melting Point145 - 148 °C
Physical DescriptionSolid
Dissociation Constants4.65
Collision Cross Section · 2 items

164.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P264, P264+P265, P270, P280, P301+P316, P305+P351+P338, P318, P321, P330, P337+P317, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 50 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

Hazard Traits - Developmental Toxicity; Reproductive Toxicity

Etodolac: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Hazard Classes and CategoriesAcute Tox. 3 (100%)

Toxicology

Hepatotoxicity · 1 item

Prospective studies show that 1% to 2% of patients taking etodolac experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations (greater than 3 fold elevated) occur in less than 1% of patients.

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Etodolac

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation · 2 items

Chemistry & industry

Pharmacology

ATC Code · 2 items

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding> 99% bound, primarily to albumin
Pharmacodynamics · 1 item

Etodolac is an anti-inflammatory agent with analgesic and antipyretic properties. It is used to treat osteoarthritis, rheumatoid arthritis and control acute pain. The therapeutic effects of etodolac are achieved via inhibition of the synthesis of prostaglandins involved in fever, pain, swelling and inflammation. Etodolac is administered as a racemate. As with other NSAIDs, the S-form has been shown to be active while the R-form is inactive. Both enantiomers are stable and there is no evidence of R- to S- conversion _in vivo_.

Mechanism of Action · 1 item

Similar to other NSAIDs, the anti-inflammatory effects of etodolac result from inhibition of the enzyme cycooxygenase (COX). This decreases the synthesis of peripheral prostaglandins involved in mediating inflammation. Etodolac binds to the upper portion of the COX enzyme active site and prevents its substrate, arachidonic acid, from entering the active site. Etodolac was previously thought to be a non-selective COX inhibitor, but it is now known to be 5 – 50 times more selective for COX-2 than COX-1. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.

Biological Half-LifeTerminal t<sub>1/2</sub>, 7.3 &plusmn; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &plusmn; 0.50 hours
Metabolism/Metabolites · 2 items

Etodolac is extensively metabolized in the liver. Renal elimination of etodolac and its metabolites is the primary route of excretion (72%). Metabolites found in urine (with percents of the administered dose) are: unchanged etodolac (1%), etodolac glucuronide (13%), hydroxylated metabolites (6-, 7-, and 8-OH; 5%), hydroxylated metabolite glucuronides (20%), and unidentified metabolites (33%). Fecal excretion accounts for 16% of its elimination.

Related reactions

14 records
New reaction record
HRID 98464 reaction equation
HRID 98464As reactant
HRID 268678 reaction equation
HRID 268678As reactant
HRID 268680 reaction equation
HRID 268680As reactant
HRID 834395 reaction equation
HRID 834395As productAs reactant
HRID 838763 reaction equation
HRID 838763As reactant
HRID 901055 reaction equation
HRID 901055As reactant
HRID 945126 reaction equation
HRID 945126As productAs reactant
HRID 946786 reaction equation
HRID 946786As productAs reactant
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

163.36 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
145 · 145-1480C
Boiling point
507.9 · 507.9±45.0 °C(Predicted)
Density
1.193 · 1.193±0.06 g/cm3(Predicted)
storage temp.
2 · 2-8°C
solubility
Practically insoluble in water, freely soluble in acetone and in ethanol (96 per cent)
form
Solid
pka
4.65 · 4.65(at 25℃)
color
White to Orange to Green
Water Solubility
40 mg/L · 40mg/L(37 ºC)
Merck
14 · 14,3874
BCS Class
2 · 2
Major Application
pharmaceutical (small molecule)
InChI
1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)
InChIKey
NNYBQONXHNTVIJ-QGZVFWFLSA-N
SMILES
CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12
CAS DataBase Reference
41340 · 41340-25-4(CAS DataBase Reference)
EWG's Food Scores
1 · 1
FDA UNII
2 M36281008 · 2M36281008
Proposition 65 List
Etodolac
NCI Drug Dictionary
etodolac
ATC code
1 AB08 · M01AB08
EPA Substance Registry System
3 · Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (41340-25-4)
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Protein binding
99 % · >99%
Excreted unchanged in urine
1 % · 1%
Volume of distribution
0.4 · 0.4
Biological half-life
6 · 6-7.4 / Unchanged
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
301 · H301
Precautionary statements
264 · P264-P270-P301+P310-P405-P501
Hazard Codes
T,Xi
Risk Statements
23 · 23/24/25-40-36-25-36/37/38
Safety Statements
22 · 22-36-45-26-36/37
RIDADR
3249 · 3249
WGK Germany
3 · 3
RTECS
360000 · UQ0360000
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
2934999090 · 2934999090
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
3 Oral · Acute Tox. 3 Oral

◉ Summary of Use during Lactation

◈ What is etodolac?

Safety data

wgk
3
rtecs
UQ0360000
ridadr
3249
hs_code
2934999090
risk_code
23/24/25-40-36-25-36/37/38
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
T,Xi
safety_code
22-36-45-26-36/37
hazard_class
6.1(b)
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
packing_group
III
Hazard statements
H301
Hazard Classifications
Acute Tox. 3 Oral
Precautionary statements
P264-P270-P301+P310-P405-P501

Etodolac has known human metabolites that include (2S,3S,4S,5R)-6-[2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid.

FDA Pharmacological Classification · 6 items

2M36281008

ETODOLAC

Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors

Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal

Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug

Etodolac is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of etodolac is as a Cyclooxygenase Inhibitor.

MeSH Pharmacological Classification · 2 items

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.

Absorption, Distribution and Excretion · 4 items

Based on mass balance studies, the systemic bioavailability of etodolac from either the tablet or capsule formulation is at least 80%.

It is not known whether etodolac is excreted in human milk; however, based on its physical-chemical properties, excretion into breast milk is expected. Etodolac is extensively metabolized in the liver. The hydroxylated-etodolac metabolites undergo further glucuronidation followed by renal excretion and partial elimination in the feces (16% of dose). Approximately 1% of a etodolac dose is excreted unchanged in the urine with 72% of the dose excreted into urine as parent drug plus metabolite.

390 mL/kg

Oral cl=49.1 mL/h/kg [Normal healthy adults]

Cellular LocationsCytoplasm
Metabolite PathwaysEtodolac Action Pathway

Uses & manufacturing

UsesUse (kg) in USA (2002): 25800
Use Classification · 2 items

Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients

Pharmaceuticals

Applications · 7 items

Uses(1) The non-steroidal anti-inflammatory drugs of Indole acetic acid class has the analgesic and anti-inflammatory effect. It can inhibit prostaglandin synthesis at the site of inflammation selectively. The product can be absorbed rapidly and has no signs of drug savings. It can be used for the treatment of rheumatoid arthritis, rheumatoid arthritis, osteoarthritis and postoperative pain relief etc. It is a medicament that suitable for elderly patients. (2) Using as anti-inflammatory drugs.

DescriptionEtodolac (etodolic acid) is a non-steroidal antiinflammatory/analgesic agent useful in the treatment of various inflammatory conditions, including rheumatoid and osteoarthritis.

Usesbetaadrenergic agonist

UsesEtodolac is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). Etodolac displays anti-inflammatory effects in both adjuvant arthritic and normal rats. E todolac is an anti-inflammatory; analgesic.

UsesFor acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.

UsesEtodolac is a non-steroidal anti-inflammatory drug (NSAID). Product Data Sheet

General DescriptionEtodolac (Lodine, Ultradol), a chiral, COX-2 selectiveNSAID drug that is marketed as a racemate, possesses an indolering as the aryl portion of this group of NSAID drugs.It shares many similar properties of this group and is indicatedfor short- and long-term management of pain and OA.Similar to ketorolac, etodolac exhibits several uniqueenantioselective pharmacokinetic properties. For example,the “inactive” (R)-enantiomer has approximately a 10-foldhigher plasma concentration than the active (S)-enantiomer.Furthermore, the active (S)-enantiomer is less protein boundthan its (R)-enantiomer and therefore has a very large volumeof distribution. It is well absorbed with an elimination halflifeof 6 to 8 hours. Etodolac is extensively metabolized intothree major inactive metabolites, 6-hydroxy etodolac (via aromatichydroxylation), 7-hydroxy-etodolac (via aromatic hydroxylation),and 8-(1'-hydroxylethyl) etodolac (via benzylichydroxylation), which are eliminated as the correspondingether glucuronides. Its unstable, acyl glucuronide, however,is subject to enterohepatic circulation and reactivation tothe parent drug, similar to other NSAIDS in this class.

Upstream & downstream products

Upstream raw materials

Chloral hydrateEthyl propionylacetate2-EthylanilineLithium Aluminum HydrideOxalyl chlorideIndole7-Ethyl tryptopholRAK 593S-EtodolacMethyl 3-oxovalerate
Additional notes · 1 item

DefinitionChEBI: A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.